CDDF
Cancer Drug Development Forum

ANNUAL REPORT 2022

Cancer Drug Development Forum (CDDF)

Table of Contents

Cancer Drug Development Forum (CDDF)

The Year in Review

Dear CDDF community,

2022 was an exciting and productive year for the CDDF as we experienced a welcome, gradual transition towards a post-pandemic world.

After working hard to ensure a successful annual conference held virtually in February when COVID-19-related restrictions were still in place, the CDDF meetings were adapted to a hybrid format from April onwards. That enabled the CDDF to reap the benefits of meeting in person while retaining the inclusivity of online attendance.

The CDDF's focus and priority in 2022 was to continue to provide a neutral platform to share current issues in cancer drug development and maintain constructive dialogue and collaboration between all stakeholders.

To this end, the CDDF gathered members of the pharma industry, regulators, academics, and patient advocates throughout the year to focus on new and ongoing topics in cancer drug development. We made use of different types of meetings, ranging from a conference, workshops to live webinars in order to best present complex issues and facilitate productive discussions.

The CDDF also aimed to increase its scope beyond Europe and establish global collaboration in cancer drug development. The initiative took shape with a joint session alongside the American Society of Clinical Oncology and the Accelerating Anticancer Agent Development and Validation (AAADV).

In addition to facilitating an ongoing dialogue on cancer treatment, the CDDF endeavored to produce educational materials and high-quality written content which can be used as a reference for future discussion.

In this effort, the CDDF has published detailed open-access meeting reports from all the events held in 2022. We are currently preparing white papers based on workshops held in the autumn to help raise awareness and call for collective action on patient access and engagement and histology independent drug development.

The Year in Review

During the past year, the CDDF developed a three-year organisational strategy to strengthen its position as a leading multi-stakeholder platform in Europe and ensure sustainable growth. This strategic plan identified four important avenues in order for the CDDF to successfully further its mission and achieve goals: effective communication, pan-European reach, diversifying stakeholders, and operational sustainability.

The organization also appointed a new chairperson of the CDDF Board and welcomed additional members so as to maintain a dynamic and diverse composition of the Board of Directors and robust governance practices.

Thanks to the industrious 2022, the CDDF moves forward confidently into 2023 with reinvigorated Board and staff members and clear strategic objectives to address topical issues and facilitate oncology drug development.

We will also continue our constructive collaboration with all our industry partners and collaborators including EMA, FDA, HTAs, academics, patient groups and oncology associations in Europe as well as all around the world.

The CDDF is grateful to all who have worked tirelessly in 2022 to advance its mission. We look forward with eagerness to working together in 2023.

Yours sincerely,

Prof. Ruth Plummer
Chairperson of the CDDF Board of Director

About the CDDF

WHAT IS THE CDDF?

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in Belgium that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in cancer drug development.

CDDF MISSION

The CDDF's mission is to facilitate collaboration between stakeholders, to **increase efficiency in cancer drug development** and **accelerate the delivery of effective oncology treatment** to patients.

HOW THE CDDF ADVANCES ITS MISSION

The CDDF provides a unique platform to facilitate collaboration between stakeholders to **increase efficiency in cancer drug development**. Our integrative approach brings together leading voices from **academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers,** and **patient groups** to improve cancer treatment.

To facilitate collaboration, the association has established **a series of meetings, workshops and webinars** to address current challenges and explore opportunities in oncology drug development. The CDDF meetings aim to **increase understanding between the various stakeholders**, and to try to **identify areas where further progress can be made**.

Organisational Structure



Ruth Plummer
Chairperson

Eva Skovlund
Vice-Chairperson

Jaap Verweij
Managing Director

Axel Glasmacher
Treasurer

Katrin Rupalla
Board member

Mark Lawler
Board member

Stefan Symeonides
Board member

Catarina Edfjall
Board member

Jaap Verweij
Managing Director

Marjorie Recorbet
Director of Operations

Giorgia Campagnano
Event Coordinator

Magdalena Strmenova
Event Coordinator

Hyunmin Park
Communication/Community Coordinator

Leadership

GOVERNANCE

CDDF Board of Directors

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs. These distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, biostatisticians, and pharmacist representing a range of perspectives within the drug development process. They have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy. The directors are elected for a period of three years.

Members of Association

Members of the CDDF are committed to accelerating oncology drug development and delivering optimal treatment to cancer patients. Members have the right to attend General Assembly meetings, which take place once a year and are the association's sovereign authority. At these meetings, Members monitor, assess and guide CDDF's work programme, organisational directions and best practices.

14
Members of the association

8
CDDF Board of Directors

4
CDDF office staff members

Leadership

CHANGES IN BOARD COMPOSITION

In accordance with the CDDF Articles of Association, a Member of the CDDF Board of Directors is appointed for a period of three years. The mandate of the member is renewable. This rotation policy serves to develop robust governance practices within the CDDF and encourages a dynamic and diverse composition of the Board of Directors.

At the CDDF's General Assembly in June 2022, the following changes were approved:

- **Prof. Ruth Plummer**, former vice-chairperson, was appointed as chair of the Board of Directors
- **Prof. Eva Skovlund**, former board member, was elected vice-chairperson
- **Prof. Axel Glasmacher** was re-elected as treasurer and **Prof. Jaap Verweij** as managing director
- **Prof. Mark Lawler**, **Dr. Katrin Rupalla** and **Prof. Stefan Symeonides** were newly appointed as board members
- **Prof. John Smyth** and **Prof. Francesco de Lorenzo** finished their terms in the CDDF board in November 2022

CONFLICTS OF INTEREST

In accordance with the Articles of Association, Board members have declared any potential conflicts of interest. The disclosure forms are provided in the appendix (page 27).

Leadership

CDDF BOARD OF DIRECTORS



CDDF Office

OFFICE STAFF MEMBERS



EMPLOYMENT DETAILS

- **Jaap Verweij, Managing Director**
  Consultancy contract renewed until 30 September 2025
- **Marjorie Recorbet, Director of Operations**
  2.5 days/week contract
- **Giorgia Campagnano**
  4 days/week contract
- **Magdalena Strmenova**
  4 days/week contract
- **Hyunmin Park**
  3 day/week contract


DIA
Duke

Financial Statement

REVENUE AND EXPENSES IN THE 2022 FISCAL YEAR

Total Revenue
€ 592,625

Total Expenses
€ 470,736

Balance*
€ 121,889

** Due to the COVID-19 pandemic, the CDDF Annual Conference 2022 had to be conducted as virtual instead of a hybrid meeting. This has reduced the planned expenses and led to a positive balance not foreseen in the approved budget. The CDDF will apply these funds to support future activities according to its articles of association.*

TOTAL REVENUE 2022

Total Revenue
€ 592,625



Financial Statement

TOTAL EXPENSES 2022

Total Expenses
€ 470,736



Achievements

OVERVIEW OF ACTIVITIES

In 2022, the CDDF converted its virtual meetings into a hybrid format as COVID-19 travel restrictions were gradually lifted worldwide. The change in the meeting format allowed for greater flexibility, increasing the potential for participants to join CDDF discussions onsite and/or online. The association also devised a schedule of webinars to bring topical issues and innovations in oncology drug development to the discussion table.

CDDF Meetings

Achievements

OVERVIEW OF ACTIVITIES

CDDF Webinar Series



CDDF BREAKS DOWN SILOS IN THE ONCOLOGY COMMUNITY AND FACILIATES OPEN, MEANINGFUL DIALOGUE AMONG ALL STAKEHOLDERS

Achievements

OVERVIEW OF ACTIVITIES

Total number of CDDF meetings in 2022	4
Total number of CDDF webinars in 2022	3
Total number of participants	624
Participant overall satisfaction rate	4.5/5

Number of Participants per Meeting/Webinar



Achievements

Categories of Onsite Meeting Participants



This graph reflects categories of onsite meeting participants in 2022

Countries of Meeting Participants



TOP 5 COUNTRIES IN EUROPE

- United Kingdom (26%)
- Belgium (20%)
- Netherlands (13%)
- Germany/Switzerland (12%)
- France (4%)

Achievements

CDDF MEETINGS IN 2022

Annual Conference 2022: Towards a Collaborative Future in Patient Access

7– 9 February 2022, online

The Annual Conference 2022 focused on the ways towards a collaborative future in patient access with a special emphasis on integration of regulatory assessment and the assessment of reimbursement of novel agents, enhancing the future of (de-central) clinical trials, lessons learned from acceleration in pediatric oncology drug development programs, and global regulatory collaborations in oncology drug development assessment.

This interactive meeting generated fruitful discussions with the following key takeaways:

- Clinical trial design will have to be adapted to the needs of both marketing approval
- assessment and health technology assessment (HTA)
- Clinical trials will increasingly be patient-centric, and organized in a decentral way.
- Multi-stakeholder collaboration proofs to be key in accelerating drug development
- The COVID-19 pandemic has strengthened international regulatory collaboration

Multi-Stakeholder Workshop (Hybrid): Measurable Residual Disease (MRD) and Circulating Tumour Nucleotides (ct DNA)

25 – 26 April 2022, Amsterdam (NL)

The workshop addressed the latest developments in the use of measurable residual disease (MRD) and circulating tumour DNA as endpoints in cancer drug development. It brought together state-of-the-art presentations on the methodological aspects, their clinical application and regulatory assessment; remarkable example of non-competitive collaboration of the pharmaceutical industry and of public-industry collaboration that are likely to deliver data on the scale that is necessary to meet the statistical criteria for the evaluation of surrogate endpoints.

Achievements

CDDF MEETINGS IN 2022

Multi-Stakeholder Workshop (Hybrid): Patient Access and Engagement in oncology drug development

19 – 20 September 2022, Amsterdam (NL)

The multi-stakeholder meeting addressed the increasingly important topic of patient access and involvement in oncology drug development and brought together experts in the field in a series of 5 sessions over two half days, delivered through a series of keynote lectures, round tables and discussion fora. Multi-stakeholder speakers and audience examined:

- ways in which patients can be empowered to be active participants in cancer research;
- how we ensure that the patient voice is amplified both in the delivery of clinical oncology research and in regulatory decision making;
- the challenging areas of reimbursement and access to innovative oncology medicines for patients;
- the absolute primacy of deploying data intelligence to underpin patient-focused oncology drug discovery and development
- challenging area of cross-border access for clinical trials in oncology

Multi-Stakeholder Workshop (Hybrid): Histology independent drug development: Is this future for cancer drugs?

14-15 November 2022, Amsterdam (NL)

The workshop explored the opportunities and challenges in tumour agnostic cancer drug development from multi-stakeholder perspectives. Attendees had in-depth discussions the challenges of single arm, small cohorts and "certainty of data". Importance of biomarker development, trial design and statistical input was emphasized in all sessions.

Achievements

CDDF WEBINARS IN 2022

Live Webinar (Online): MRD by NGS in patients with AML undergoing allogeneic transplantation

24 February 2022

The CDDF organized a live webinar on the topic of Measurable Residual Disease in Acute Myeloid Leukemia on Thursday 24 February 2022. This webinar was composed of a 25-minute lecture given by Dr. Christopher Hourigan (National Institutes of Health, US) followed by a 30-minute discussion session moderated by Prof.John Smyth (CDDF, UK) and Prof. Axel Glasmacher (CDDF, DE).

Live Webinar (Online): Challenges and opportunities in the new era of immunotherapy and radiotherapy combinations

5 May 2022

In this webinar held on 5 May 2022, Prof. Charles B. Simone gave a presentation on challenges and opportunities in the new era of immunotherapy and radiotherapy combinations and participated in a discussion session moderated by Prof. Axel Glasmacher (CDDF, DE) and Dr. Sophia Pfister (Varian, US). The webinar provided insights into the following timely and critical topics:

(1) Are all radiation modalities the same? What is the recent development in radiotherapy?
(2) What is the recent development in immunotherapy including and beyond checkpoint blockade?
(3) Lessons learned from clinical trials of combination therapy, and what are the emerging opportunities for immune-RT combinations?

Achievements

CDDF WEBINARS IN 2022

Live Webinar (Online): Diversity in Clinical Trials

26 September 2022

This webinar was composed of a 15-minute lecture given by Prof. Dr. Marie von Lilienfeld-Toal (University of Jena, DE) & 15-minute lecture given by Dr. Lola Fashoyin-Aje (FDA, US). It was followed by a 30-minute discussion session moderated by Prof. Axel Glasmacher (CDDF, DE) and Sushmita Sen (Roche, CH).

The speakers and moderators discussed missed opportunities when clinical trials are not representative of the real-world population and also missed opportunities for improving patient outcomes. To ensure scientific advances are beneficial and equitable to all relevant patient populations, the webinar concluded that inclusive trial designs with appropriate representation of vulnerable and disadvantaged populations need be considered.

Achievements

COLLABORATION

The CDDF believes that collaboration is key to its mission. In 2022 it established and maintained close collaborations with the following organizations representing various perspectives in cancer drug development:

EORTC

The European Organisation for Research and Treatment of Cancer (EORTC) and the CDDF continued their active collaboration through a series of clinical cancer research-related workshops and webinars covering all aspects of cancer treatment, from early drug development to accessing therapeutic modalities.

34th EORTC-NCI-AACR Symposium (October 2022)

Prof. Jaap Verweij (CDDF,NL) was invited to the 34th EORTC-NCI-AACR Symposium and moderated a panel discussion session on modernising eligibility criteria for early phase oncology clinical trials.

IBCD Meeting (October 2022 - postponed until 2023)

Prof. Jaap Verweij (CDDF,NL) and Prof. Eva Skovlund (CDDF, No) served as program committee members of the Innovations and Biomarkers in Cancer Drug Development Conference (IBCD) meeting. They provided EORTC with their scientific knowledge and expertise and contributed to the development of the meeting program.

Achievements

COLLABORATION

AAADV

The CDDF continued its close collaboration with the Accelerating Anticancer Agent Development and Validation (AAADV), exchanging best practices and information on cancer drug development globally.

September 2022

The CDDF-AAADV-ASCO held a joint online meeting on global cancer drug development. Prof. Jaap Verweij (CDDF, NL) took part in its program committee to provide scientific inputs and guidance and also served as a moderator.

Prof. Axel Glasmacher contributed to the joint session by giving an introductory presentation on ctDNA for cancer detection, prognostication and monitoring efficacy and moderating discussions.

EFPIA

The CDDF maintained a close tie with the European Federation of Pharmaceutical Industries and Associations (EFPIA) by taking part in its virtual meetings and listening to voices from the industry.

EMA & FDA

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) continued their support for CDDF multi-stakeholder discussions in 2022 and were actively involved in CDDF's meetings. Both agencies provided valuable regulatory perspective on diverse topics in cancer drug development and took part in constructive discussions with CDDF multi-stakeholder community .

Achievements

COLLABORATION

WECAN

The Workgroup of European Cancer Patient Advocacy Networks (WECAN) and the CDDF made joint efforts to continuously push for the shared mission to improve cancer treatment. The WECAN and its representatives have served in various roles at CDDF meetings, helping the CDDF to better incorporate the patient perspective into multi-stakeholder discussions.

To further encourage patients' engagement ad empower their voice in discussions, the CDDF continued providing patient grants which are devised to ease their logistical obstacles.

ECPC

The CDDF, with support from the European Cancer Patient Coalition (ECPC), made continued efforts to acknowledge and share patient views on opportunities and challenges in cancer drug development.

Acknowledgement of Supporters

The CDDF thanks all partners and collaborators for their engagement and valued input to support the CDDF's mission in 2022.

CDDF INDUSTRY PARTNERS IN 2022

AstraZeneca
basilea
BAYER
blueprint MEDICINES
Bristol-Myers Squibb
Daiichi-Sankyo
Eisai
Genmab
gsk
HELSINN
Building quality cancer care together
J&J
Lilly
MERCK
MSD
NORTHWEST BIOTHERAPEUTICS
NOVARTIS
Roche
Seagen
SERVIER
SIEMENS Healthineers

Acknowledgement of Supporters

COLLABORATORS IN 2022



CDDF in 2023: A Look Ahead

CDDF'S FOCUS IN 2023

Key Discussion Topics in Cancer Drug Development

The CDDF Board of Directors have selected high-priority topics in cancer drug development. Discussion topics listed below will be explored and examined at CDDF webinars and multi-stakeholder meetings. The CDDF is committed to collaborating with diverse stakeholders to successfully develop and execute meeting programmes throughout 2023.

CDDF WEBINARS IN 2023

- Decentralized care
- Europe's Beating Cancer Plan
- EU clinical trials regulation
- EU HTA regulation
- Clinical research in Central and Eastern Europe
- Preventive cancer care
- COVID-19 and impact on cancer patients, treatments and developments

CDDF in 2023: A Look Ahead

CDDF MEETINGS IN 2023

Annual Conference 2023 (Hybrid)

Challenges in clinical trial performance

6 – 8 February 2023, Noordwijk (NL)

Multi-Stakeholder Workshop (Hybrid)

Dose Optimization in Early Oncology Drug Development

3 – 4 April 2023, Amsterdam (NL)

Multi-Stakeholder Workshop (Hybrid)

Pnnovative Oncology Trial Designs

18 – 19 September 2023, Amsterdam (NL)



Multi-Stakeholder Workshop (Hybrid)

The Critical Role of Biomarkers in Delivering Drug Development-Related Precision Oncology

13 -14 November 2023, Amsterdam (NL)

Appendix

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Ruth Plummer

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Immunocore, Genmab, Astex Therapeutics,Medivir, and Sanofi Aventis.
- Honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo and SOTIO Biotech AG, and AstraZeneca
- Payment for the delivery of educational talks or chairing educational meetings from AstraZeneca, Novartis, Bayer and BMS.
- Funds to support attendance at conferences from MSD and BMS.

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 14 March 2023

Prof. Eva Skovlund

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 8 March 2023

Appendix

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Jaap Verweij

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Deuter Oncology
- IDRx
- Boehringer Ingelheim
- Galecto
- Ellipses
- Helsinn
- NanoGhost

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 8 March 2023

Prof. Axel Glasmacher

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of Board of Directors (Current)
  - 4D Pharma plc (chairperson)
  - Active Biotech AB
  - Ryvu Pharmaceuticals
- Consultancy/other honoraria (in the last two years)
  - Bristol-Myers Squibb
  - Active Biotech AB
  - Nanexa AB
  - Cellex GmbH

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 12 December 2022

Appendix

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Catarina Edfjäll

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Novo Nordisk (Consulting)
- ObsEva (Board member)

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 15 February 2022

Prof. Mark Lawler

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Bayer, EMD Serono, Novartis, Pfizer and Roche (honoraria unrelated to the current work)
- Carnall Farrar (honorarium unrelated to the current work)

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 14 December 2022

Appendix

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Katrin Rupalla

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 5 June 2022

Prof. Stefan Symeonides

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Consultancy (my institution):
  - Ellipses (11/4/18 -)
  - Vaccitech (1/2/18 -)
  - Duke Street Bio (22/3/22 -)
  - Eugit Therapeutics (10/22 -)
- Scientific advisory role (my institution):
  - Eisai (18/3/19, -)
  - MSD (17/3/22, -)
  - BMS (21/6/19, -)
- Research funding (my institution):
  - MSD (trial funding and drug supply, trials staff) (6/15-)
  - Verastem (trial funding and drug supply) (6/15-)

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Last updated on 3 November 2022

Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels.
Enterprise number: 738.523.752

info@cddf.org
www.cddf.org
@cddf_eu
The Cancer Drug Development Forum (CDDF)